ClinicalTrials.gg
RecruitingNCT06552429Updated Nov 17, 2025

Peginterferon α-2b Injection for Hydroxyurea Resistant or Intolerant ET

A Phase 2 interventional study of Peginterferon α-2b injection and Peginterferon α-2b injection in Essential Thrombocythemia, sponsored by Xiamen Amoytop Biotech Co., Ltd.. Recruiting at 8 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-17.

Sponsored by Xiamen Amoytop Biotech Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Thrombocythemia, Essential with a site in China — 6 open to participants now, 10 under way, 3 of them phase 3. Thrombocythemia, Essential · China.

Started
2024
with 3 others
Phase 2
2 of 11
2 open now
Registered
10th of 11
by date
Lead sponsor
1 of 11
Xiamen Amoytop Biotech Co., Ltd.

Among the 11 studies in Thrombocythemia, Essential with a site in China, this one is one of 4 that started in 2024, is one of 2 in phase 2, and was the 10th registered.

Thrombocythemia, Essential

229 studies on the registry are indexed under Thrombocythemia, Essential; 38 are open to participants now.

Browse Thrombocythemia, Essential studies →

Open to participants now

6 of the 11 studies in Thrombocythemia, Essential with a site in China are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 34 Thrombocythemia, Essential studies recruiting now, 30 (88%) set no upper age limit and 3 (9%) stop at 75 or younger; 5 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Thrombocythemia, Essential with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, randomized, open-label Phase 2 clinical study. It is aimed to enroll 27 essential thrombocytopenia (ET) patients who are resistant to or intolerant of hydroxyurea(HU). Eligible patients will be randomized to receive either Peginterferon α-2b 135 mcg or Peginterferon α-2b 180 mcg at a ratio of 1:2, and all subjects will go through a target treatment period (Weeks 1 \~ Week 48), an extension treatment period (Weeks 49 \~ Week 96) and a follow-up period (Weeks 97 \~ Week 100). Pharmacokinetics, safety, efficacy will be evaluated.

03

Conditions studied

  • Essential Thrombocythemia

Keywords

  • Essential Thrombocythemia
  • Peginterferon α-2b
  • hydroxyurea resistant
  • hydroxyurea intolerant
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects, aged greater or equal to 18 years old at screening;
  • Subjects diagnosed as high-risk ET according to the World Health Organization (WHO) 2016 criteria:1) who is older than 60 years and JAK2V617F positive at screening, 2) or who previously suffered from disease-related thrombosis or hemorrhage;
  • Subjects who have previously received HU for ET, and the time interval between the last HU dose and the first dose of the study drug should not be less than 7 days;
  • Interferon treatment-naïve, and for those who have previously received interferon the the time interval between the last dose of interferon and randomization should not be less than 1 month;
  • Patients with confirmed hydroxyurea resistance or intolerant, as at least one of the following criteria is met:

    1. count remain greater than 600×10\^9 /L after at least 3 months of HU treatment at a dose ≥2g/d (dose ≥2.5 g/d if subject weight > 80 kg);
    2. Platelet count greater than 400*10\^9/L while white blood cell (WBC) count lower than 2.5*10\^9/L, or platelet count greater than 400*10\^9 /L while lower than 100 g/L at any dose of HU;
    3. Presence of HU-related toxicities at any dose of HU: e.g. ulcers in legs, or any unacceptable skin mucosal manifestations or fever;
  • Platelet counts > 450*10\^9/L at screening;
  • ≥1.0*10\^9/L at screening;
  • Haemoglobin ≥11 g/dL at screening for males and 10 g/dL for females at screening;
  • There is no serious function damage in liver and kidney: total ≤1.5 (ULN), ≤2.0 ULN, aspartate aminotransferase≤2.0 ULN, is prolonged by less than 4 seconds, ≥50 mL/min (according to Cockcroft-Gault formula) at screening;
  • Both male and female subjects must agree take an appropriate method, including:

    1. Male subjects: must agree to use reliable contraception from inform consent until 6 months following the last dose of the study drug.
    2. Female subjects: Must meet at least one of the following conditions:

    i) Women without ; ii) Women of childbearing potential: no pregnant or breastfeed, negative in blood pregnancy test within 4 days prior to the first dosing, and must agree to use reliable contraception from inform consent until 6 months following the last dose of the study drug;

  • Subjects understand the objective, characteristic, method and possible adverse reactions of the study, voluntarily participate in this study, and sign .

Exclusion criteria

Exclusion Criteria:

  • History of any other myeloproliferative tumors, or evidence of the presence of any other myeloproliferative tumors;
  • or to interferons of any of its ;
  • Severe medical conditions or serious comorbidities that the investigators determined could jeopardize the safety or protocol adherence, e.g. [NYHA] Class III-IV, congestive heart failure, symptomatic arrhythmias,pulmonary hypertension;
  • History of major organ transplantation;
  • Documented disease or history of autoimmune disease at screening, e.g. medication un-controlled thyroid dysfunction, autoimmune hepatitis, idiopathic thrombocytopenic purpura, scleroderma, psoriasis, or any autoimmune arthritis;
  • pulmonary infiltration, infectious pneumonia, and non-infectious pneumonia at screening that, in the investigator's opinion, would jeopardize the safety of the subject or their compliance with the protocol;
  • Infection with systemic clinical manifestations at screening, e.g., bacteria, fungi, , excluding and/or C;
  • Evidence of severe retinopathy, e.g., cytomegalovirus retinitis, symptomatic macular degeneration, or clinically significant eye disease, e.g. due to diabetes mellitus or hypertension;
  • Diagnosed clinically significant depression or a history of depression and, in the investigator's opinion, previous suicide attempts or at any risk of suicide at screening;
  • Diagnosed clinically significant neurological disease or a history of clinically significant neurological disease, except for a history of stable cerebral thrombosis or cerebral hemorrhage;
  • History of any within 5 years (except stage 0 chronic lymphocytic leukemia, basal cell carcinoma, squamous cell carcinoma, and superficial melanoma);
  • A history of alcohol or drug abuse within 1 year;
  • Have used any drug within 4 weeks prior to first dose of investigational drug, or not recovered from the effects of prior investigational drug administration;
  • Other situations that, in the investigator's opinion, not appropriate for inclusion.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
27 participants (estimated)

Study arms

  • Experimental
    Peginterferon α-2b 135 mcg dose group

    Drug: Peginterferon α-2b injection

  • Experimental
    Peginterferon α-2b 180 mcg dose group

    Drug: Peginterferon α-2b injection

Interventions

  • Peginterferon α-2b injection, 135 mcg, s.c., once a week, during the targeted treatment period (the first 48 week), peginterferon α-2b dose is depended on the patient's response and tolerability during the extension treatment (week 49 to week 96).

  • Peginterferon α-2b injection, 180 mcg, s.c., once a week, during the targeted treatment period (the first 48 week), peginterferon α-2b dose is depended on the patient's response and tolerability during the extension treatment (week 49 to week 96).

06

What researchers measure

Primary outcomes

  1. Maximum concentration (Cmax)

    Time frame: week1,4, 8, 12, 24, 36, 48, 60, 72, 84, 96.

  2. Time to maximum concentration (Tmax)

    Time frame: week1,4, 8, 12, 24, 36, 48, 60, 72, 84, 96.

  3. Area under the plasma concentration-time curve

    Time frame: week1,4, 8, 12, 24, 36, 48, 60, 72, 84, 96.

  4. Apparent volume of distribution after oral administration (Vz/f)

    Time frame: week1,4, 8, 12, 24, 36, 48, 60, 72, 84, 96.

  5. Apparent plasma clearance (CL/F)

    Time frame: week1,4, 8, 12, 24, 36, 48, 60, 72, 84, 96.

  6. Plasma elimination half-life (t1/2)

    Time frame: week1,4, 8, 12, 24, 36, 48, 60, 72, 84, 96.

  7. Relationship between exposure and the effect (desired-effectiveness or undesirable-toxicity) in a pharmacokinetic model and pharmacodynamic model.

    Time frame: up to 96 weeks.

Secondary outcomes

  1. Rate of complete hematological remission.

    Time frame: Week 24, 36, 48, 60, 72, 84, 96.

  2. Platelet counts change from baseline.

    Time frame: Week 12, 24, 36, 48, 60, 72, 84, 96.

  3. White blood cell counts change from baseline.

    Time frame: Week 12, 24, 36, 48, 60, 72, 84, 96.

  4. Complete remission rate.

    Time frame: Week 24, 36, 48, 60, 72, 84, 96.

  5. Time to complete remission from baseline.

    Time frame: Week 48, 96.

  6. Duration of complete remission.

    Time frame: Week 48, 96.

  7. Remission rate of bone marrow.

    Time frame: Week 48, 96.

  8. Incidence of disease progression.

    Time frame: Week 48, 96.

  9. Change of JAK2V617F mutations load from baseline.

    JAK2V617F mutations were quantitatively detected using next-generation sequencing

    Time frame: Week 48, 96.

  10. Change of CALR mutations load from baseline.

    CALR mutations were quantitatively detected using next-generation sequencing

    Time frame: Week 48, 96.

  11. Change of MPL mutations load from baseline.

    MPL mutations were quantitatively detected using next-generation sequencing

    Time frame: Week 48, 96.

  12. Change of MPN-SAF TSS scores from baseline

    Time frame: Week 12, 24, 36, 48, 60, 72, 84,96.

  13. Change of spleen size from baseline

    The maximum length of the spleen was measured by ultrasound.

    Time frame: Week 12, 24, 36, 48, 60, 72, 84, 96.

  14. Rate of complete hematological remission maintenance in patients received dose-reduction extension therapy

    Time frame: Week 96.

  15. Duration of complete hematological remission in patients received dose-reduction extension therapy

    Time frame: Week 96.

  16. Change of 3-level Version of EuroQol Five Dimensions(EQ-5D-3L) scores from baseline.

    Time frame: Week 12, 24, 36, 48, 60, 72, 84, 96.

  17. Incidence of thrombotic and bleeding events.

    Time frame: through study completion, an average of 2 year

07

Study locations

8 of 8 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2024 to primary completion in Oct 2025, 13 months.

Of 27 phase 2 interventional studies under Thrombocythemia, Essential, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 141. This study's 13 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 27, 2024
First posted
Aug 14, 2024
StartActual
Aug 29, 2024
Primary completionActual
Oct 26, 2025
CompletionEst.
Sep 2027
Last update
Nov 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06552429
Responsible party
Sponsor
First posted
Aug 14, 2024
Start date
Aug 29, 2024
Primary completion
Oct 26, 2025
Completion
Sep 2027 (estimated)
Last update
Nov 17, 2025

Study contacts

Lei Zhang
Contact
zhanglei1@ihcams.ac.cn
13502118379
Rongfeng Fu
Contact
furongfeng@ihcams.ac.cn
13502118379
Lei Zhang
principal investigator · Chinese Academy of Medical Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Peginterferon alfa-2b

Start the discussion